Zeltia S.A. engages in the management, support and promotion of its investees, essentially in the chemical-pharmaceutical sector, and the acquisition and refurbishment of real estate for lease. PharmaMar, S.A., a biopharmaceutical company and a subsidiary of Zeltia, operates in the oncology field. It provides cancer care through the discovery and development of drugs based on marine-derived agents. PharmaMar’s agents in clinical development include Yondelis, Aplidin, and Kahalalide-F in Phase II clinical trials; and ES-285 in Phase I clinical trials. GENOMICA, S.A., wholly owned by Zeltia, engages in the development, manufacture, and supply of Molecular Diagnosis Kits for the detection of various viruses and bacteria, as well as product applications targeting oncology and environmental investigation and analysis. GENOMICA also provides a range of specialist DNA Analysis Services covering the needs of the legal profession, paternity and family lineage investigation, as well as in several veterinary applications, including genetic fingerprinting. Zelnova, S.A., another wholly owned subsidiary of Zeltia, produces and markets cleaning and hygiene products for households, industry, and the hotel and catering sector. Its product lines include air fresheners, domestic cleaning agents, and insecticides. Zeltia’s wholly owned subsidiary, Xylazel, S.A., specializes in manufacturing and marketing paints, varnishes, and protective products for wood for the Do-It Yourself, Trade, and Industrial sectors. PROMAX, S.A. is also a company, pertaining to the Zeltia Group, which engages in the treatment, protection, and restoration of monument wood and buildings. Neuropharma S.A.U. is a biopharmaceutical company that was founded in 2000 and in which the Zeltia group has 100% equity holdings. Centring on the research into and development of new medicines for the treatment and prevention of diseases affecting the nervous system, Neuropharma is born with the idea of exploiting the huge library of marine compounds that Pharmamar has in another therapeutical area that does not cover the field of cancer. Its sample bank includes approximately 40,000 samples with a marine origin, of which between 2% and 3% show pharmacological activity as compared with the therapeutical centres that have been studied. Its main line of action focusses on neurodegenerative diseases, and in particular on Alzheimer’s disease. Significant Events The company has formed a subsidiary, Sylentis. The subsidiary would focus its research efforts on the causes of glaucoma and on Crohn's disease. History Zeltia S.A. was incorporated in 1939.
zeltia sa (ZLIXF:OTC US)
Plaza del Descubridor Diego de Ordás, 3
Phone: 34 91 444 45 00
Fax: 34 91 593 29 54www.zeltia.com
|No competitor information is available for ZLIXF.|
|View Industry Companies|
Sponsored Financial Commentaries
To contact ZELTIA SA, please visit www.zeltia.com. Company data is provided by Capital IQ. Please use this form to report any data issues.